RecruitingPhase 2Phase 3NCT06653348

Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke

De-Escalation of Dual Antiplatelet Therapy With Ticagrelor and Aspirin in Non-disabling Non-cardioembolic Ischemic Stroke or High Risk TIA Patients: A Randomized, Outcome Assessor Blind, Controlled Trial

Sponsor

Mazandaran University of Medical Sciences

Enrollment

100 participants

Start Date

Apr 1, 2024

Study Type

INTERVENTIONAL

Conditions

Ischemic Stroke Transient Ischemic Attack

Summary

This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.

Eligibility

Min Age: 40 Years

Inclusion Criteria7

signing inform consent,
recent ischemic stroke within 24 h,
diagnosed by brain CT or MRI mild stroke with NIHSS =\<8 and no evidence of large infarct in brain imaging
high risk TIA with ABCD \>4,
no cardioembolic source such as low E/F, MS, AF ,...
no specific etiology such as dissection, vasculitis, ...
no carotid stenosis \> 50 % in side of involvement

Exclusion Criteria9

history of hypersensitivity to consumptive drug
any indication for anticoagulant therapy
acute phase treatment with intravenous thrombolysis or thrombectomy
any contraindication for consumptive drug
history of intracranial hemorrhage
history of GI bleeding during past 6 m
candidate for endarterectomy
history of coagulopathy
active hemorrhagic diathesis during randomization

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTicagrelor 60 + Aspirin

Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 6.

DRUGTicagrelor 90 + aspirin

ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.

Locations(1)

Mazandaran province, Sari,Iran

Sari, Mazandaran, Iran

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06653348

Related Trials

Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2)

NCT073759661 location

Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK)

NCT073759531 location